Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist
SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
SHANGHAI, Sept. 14, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that it has filed investigational new drug application (IND) with US FDA for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42. ASC42 is an in-...
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement aiming at combination therapy of ASC41 ...
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
HANGZHOU and SHAOXING, China, Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC co...
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
HANGZHOU, China and SHAOXING, China, Aug. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody. ASC22(Envafolimab) Phase IIa clin...
Ascletis' All-oral HCV Treatment Approved for Marketing in China
HANGZHOU and SHAOXING, China, July 31, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its all-oral HCV treatment has been approved for marketing inChina by National Medical Products Administration (NMPA). The Company's all-oral HCV treatment (RDV/DNV Regimen) is ...
Bridging Study in China Completed for NASH Drug Candidate ASC40
HANGZHOU and SHAOXING, China, July 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) in 34 Chinese subjects has been completed and data indicate...
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
HANGZHOU, China and SHAOXING, China, June 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its partner Sagimet Biosciences Inc (Sagimet, formerly 3-V Biosciences Inc), announced today positive results on oral, once-daily non-alcoholic steatohepatitis (NASH) dru...
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
HANGZHOU, China and SHAOXING, China, May 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from China's National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-al...
Ascletis Receives IND Approval for its HIV Drug ASC09F
HANGZHOU and SHAOXING, China, April 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose C...
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
HANGZHOU and SHAOXING, China, April 1, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its partner Sagimet Biosciences (formerly 3-V Biosciences, Inc), will present clinical and preclinical data on non-alcoholic steatohepatitis (NASH) drug candidate TVB-2640 (Ascl...
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
HANGZHOU and SHAOXING, China, March 25, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the first clinical study using Ganovo®(danoprevir) to treat naive and experienced COVID-19 patients was published in medRxiv. The data from this small-sample clinical study showed ...
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
HANGZHOU, China and SHAOXING, China, March 10, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the progress of the small sample clinical trial of Ganovo® and Ritonavir combination therapy on Novel Coronavirus Pneumonia. One of the treatment groups in this study is the ...
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
HANGZHOU and SHAOXING, China, Feb. 27, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the advancement in Novel Coronavirus Pneumonia clinical trial of oral Ganovo® and Ritonavir combination therapy, led by Dr. Hongyi CHEN, the director of the Ninth Hospital ofNanchang...
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
HANGZHOU, China and SHAOXING, China, Feb. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted byChina's National Medical Products Administration (NMPA)...
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients inChina from China's National Medical Products Administration. ASC22 is a first-in-class, subcuta...
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
HANGZHOU, China and SHAOXING, China, Nov. 29, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ascle...
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
